392 related articles for article (PubMed ID: 11747330)
1. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation.
Stratigos AJ; Kapranos N; Petrakou E; Anastasiadou A; Pagouni A; Christofidou E; Petridis A; Papadopoulos O; Kokka E; Antoniou C; Georgala S; Katsambas AD
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):180-6. PubMed ID: 15752287
[TBL] [Abstract][Full Text] [Related]
3. Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma.
Bäckvall H; Strömberg S; Gustafsson A; Asplund A; Sivertsson A; Lundeberg J; Ponten F
Exp Dermatol; 2004 Oct; 13(10):643-50. PubMed ID: 15447725
[TBL] [Abstract][Full Text] [Related]
4. Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV radiation-induced basal cell carcinoma.
Weihrauch M; Bader M; Lehnert G; Wittekind C; Tannapfel A; Wrbitzky R
Int Arch Occup Environ Health; 2002 Apr; 75(4):272-6. PubMed ID: 11981662
[TBL] [Abstract][Full Text] [Related]
5. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
Ansarin H; Daliri M; Soltani-Arabshahi R
Eur J Dermatol; 2006; 16(5):543-7. PubMed ID: 17101476
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma--five years survival rate].
Hofele C; Schwager-Schmitt M; Volkmann M
Laryngorhinootologie; 2002 May; 81(5):342-5. PubMed ID: 12001023
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin.
Einspahr J; Alberts DS; Aickin M; Welch K; Bozzo P; Grogan T; Nelson M
Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):583-7. PubMed ID: 9264270
[TBL] [Abstract][Full Text] [Related]
9. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
[TBL] [Abstract][Full Text] [Related]
10. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cells, immunomodulation and skin lesions. A quantitative, morphological and clinical study.
Bergfelt L
Acta Derm Venereol Suppl (Stockh); 1993; 180():1-37. PubMed ID: 7901956
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients.
Warnakulasuriya S; Soussi T; Maher R; Johnson N; Tavassoli M
J Pathol; 2000 Sep; 192(1):52-7. PubMed ID: 10951400
[TBL] [Abstract][Full Text] [Related]
13. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
15. Infrequent p53 mutations in arsenic-related skin lesions.
Castrén K; Ranki A; Welsh JA; Vähäkangas KH
Oncol Res; 1998; 10(9):475-82. PubMed ID: 10223623
[TBL] [Abstract][Full Text] [Related]
16. A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer.
Prior SL; Griffiths AP; Lewis PD
Br J Dermatol; 2009 Nov; 161(5):1067-71. PubMed ID: 19624548
[TBL] [Abstract][Full Text] [Related]
17. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
Jezersek B; Rudolf Z; Novakovic S
Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
[TBL] [Abstract][Full Text] [Related]
18. Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma.
Bäckvall H; Asplund A; Gustafsson A; Sivertsson A; Lundeberg J; Ponten F
Mutat Res; 2005 Apr; 571(1-2):65-79. PubMed ID: 15748639
[TBL] [Abstract][Full Text] [Related]
19. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.
Hsu CH; Yang SA; Wang JY; Yu HS; Lin SR
Br J Cancer; 1999 Jun; 80(7):1080-6. PubMed ID: 10362120
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.
Bolshakov S; Walker CM; Strom SS; Selvan MS; Clayman GL; El-Naggar A; Lippman SM; Kripke ML; Ananthaswamy HN
Clin Cancer Res; 2003 Jan; 9(1):228-34. PubMed ID: 12538474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
